This upcoming NIH grant will fund innovative research developing advanced bioinformatics and computational biology tools to improve biomedical data analysis and health outcomes, encouraging interdisciplinary and technology-driven projects.
Funder: National Institutes of Health
Due Dates: November 5, 2026 (Renewal/resubmission/revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/resubmission/revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/resubmission/revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/resubmission/revision) | February 5, 2028 (New) | March 5, 2028 (Renewal/resubmission/revision) | June 5, 2028 (New) | July 5, 2028 (Renewal/resubmission/revision) | October 5, 2028 (New) | November 5, 2028 (Renewal/resubmission/revision) | February 5, 2029 (New) | March 5, 2029 (Renewal/resubmission/revision; final deadline)
Funding Amounts: Up to $250,000 annually in direct costs for up to 4 years; $2,500,000 estimated program funding
Summary: Supports innovative, broadly applicable bioinformatics, translational bioinformatics, and computational biology methods and tools that advance biomedical discovery and health.
Key Information: Foreign organizations may apply, but applications involving foreign subawards or subcontracts are ineligible for funding.
The National Library of Medicine (NLM), part of NIH, supports R01 research developing innovative methods, tools, and approaches in bioinformatics, translational bioinformatics, and computational biology. The program seeks to extract actionable knowledge from complex biological datasets through technologies such as artificial intelligence, machine learning, and large-scale computational platforms, ultimately improving individual and population health.
Projects may address omics and multi-omics, microbiomes, genetic variation, phenotypes, biological networks, single-cell informatics, biomarkers, drug targets, personalized medicine, and biological data integration or reuse. NLM encourages interdisciplinary collaboration, scalable and autonomous innovations, and complete usable workflows. Emphasis is on moving beyond prediction toward functional insights into biological phenomena and disease mechanisms. Outputs should be transformative, durable, and generalizable beyond a single disease or biological system. Clinical trials are optional.